News

Technology News

Alector Accepts Series C Financing

Thursday, September 17, 2015 5:03:00 AM PDT | VentureDeal
   San Francisco, California  --  Biotechnology company Alector has secured $32 million in its third round of institutional venture capital funding.

Alector is combining antibody technology with recent discoveries in narrow immunology and human genetics to develop therapeutic candidates for Alzheimer's disease, other forms of dementia and neurodegenerative disorders.

The Merck Research Laboratory led the round, which included previous investors OrbiMed, Polaris Partners, Google Ventures, Topspin Partners and Mission Bay Capital.

Alector said it would use the funding to broaden its drug pipeline in advance its most promising candidates toward clinical trials.

Company CEO Arnon Rosenthal also founded the firm in May, 2013 and previously worked at Rinat Neuroscience and Genentech.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1